Arena Pharmaceuticals, Inc.

Press Releases



All Releases

View Summary Arena Pharmaceuticals Announces Third Quarter 2014 Conference Call and Webcast on Monday, November 3
Oct 27, 2014
PDF 12.1 KB Add to Briefcase
View Summary Eisai and Arena Pharmaceuticals Announce Presentation of Lorcaserin HCl Data at the American College of Clinical Pharmacy Annual Meeting
Oct 13, 2014
PDF 18.3 KB Add to Briefcase
View Summary Eisai and Arena Pharmaceuticals Announce Publication of Pooled Phase 3 Clinical Trial Analysis of BELVIQ® (lorcaserin HCl) CIV in Postgraduate Medicine
Oct 10, 2014
PDF 51.6 KB Add to Briefcase
View Summary Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
Sep 22, 2014
PDF 10.4 KB Add to Briefcase
View Summary Lorcaserin HCl Data to be Presented at the American Society of Bariatric Physicians' 64th Annual Obesity & Associated Conditions Symposium
Sep 10, 2014
PDF 19.6 KB Add to Briefcase
View Summary Arena Pharmaceuticals' APD811 Granted Orphan Drug Status for Pulmonary Arterial Hypertension
Sep 2, 2014
PDF 11.6 KB Add to Briefcase
View Summary Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results
Aug 1, 2014
PDF 24.6 KB Add to Briefcase
View Summary Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity
Jul 30, 2014
PDF 17.4 KB Add to Briefcase
View Summary Eisai and Arena Pharmaceuticals Announce BELVIQ® (lorcaserin HCl) CIV Nominated a Second Time for the Prix Galien Award in the Best Pharmaceutical Agent Category
Jul 29, 2014
PDF 18.1 KB Add to Briefcase
View Summary Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1
Jul 25, 2014
PDF 10.4 KB Add to Briefcase
View Summary Arena Pharmaceuticals Enters into Marketing and Supply Agreement for BELVIQ® (lorcaserin HCl) in Israel
Jul 21, 2014
PDF 12.7 KB Add to Briefcase
View Summary Arena Pharmaceuticals Issued Patent for APD371 by United States Patent and Trademark Office
Jul 15, 2014
PDF 11.5 KB Add to Briefcase
View Summary Arena Pharmaceuticals Reports that Eisai Completes Planned Increase in Sales Force for BELVIQ® (lorcaserin HCl) CIV
Jul 10, 2014
PDF 16.5 KB Add to Briefcase
View Summary Arena Pharmaceuticals to Present at the 2014 Wells Fargo Securities Healthcare Conference
Jun 13, 2014
PDF 10.5 KB Add to Briefcase
View Summary Lorcaserin HCl Data to be Presented at American Diabetes Association's 74th Scientific Sessions
Jun 9, 2014
PDF 49.6 KB Add to Briefcase
View Summary Arena Pharmaceuticals Initiates Phase 1b Clinical Trial of APD334 for Autoimmune Diseases
Jun 3, 2014
PDF 11.3 KB Add to Briefcase
View Summary Arena Pharmaceuticals to Present at the Jefferies 2014 Global Healthcare Conference
May 27, 2014
PDF 10.4 KB Add to Briefcase
View Summary Arena Pharmaceuticals Provides Corporate Update and Reports First Quarter 2014 Financial Results
May 12, 2014
PDF 21.6 KB Add to Briefcase
View Summary Arena Pharmaceuticals Reports that Eisai Plans to Further Increase its Sales Force for BELVIQ® (lorcaserin HCl) CIV by 50%
May 9, 2014
PDF 17.4 KB Add to Briefcase
View Summary Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Monday, May 12
May 5, 2014
PDF 10.6 KB Add to Briefcase
Showing 21-40 of 481 Page: 1 2 3 4 5 6 ... 25  Previous 20 | Next 20
Add to Briefcase = add release to Briefcase